Tolerability and clinical efficacy of desmin in the treatment of superficial thrombovaricophlebitis

Angiology

Volumn 47, Issue 9, 1996, Pages 887-894

  Andreozzi, Giuseppe Maria ^a   Signorelli, Salvatore ^a   Di Pino, Luigi ^a   Martini, Romeo ^a   Marchitelli, Elsa ^b   Pinto, Antonio ^a   Romeo, Salvatore ^a   Zamboni, Villiam ^c   Palazzini, Ernesto ^c   Pepe, R ^b   Gloria, R ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c Alfa Wassermann SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DESMIN;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PROTHROMBIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOPHLEBITIS; VARICOSIS;

EID: 9544222602     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979604700907     Document Type: Article

References (23)

1. Ofosu FA, Fernandez F, Anvari N, et al: Further studies on the mechanism for the antithrombotic effects of polysaccharides in rabbits. Thromb Haemost 60:188-192, 1988.
2. Sie P, Ofosu FA, Fernandez F, et al: Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of various sulphated polysaccharides. Br J Hemat 64:707-714, 1986.
3. Tollefsen DM, Petska CA, Monafo WJ: Activation of heparin cofactor II by dermatan sulphate. J Biol Chem 258:6713-6716, 1983.
4. Tripodi A, Moia M, Bottasso B, et al: Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 62:663-672, 1991.
5. Ofosu FA, Buchanan MR, Anvari N, et al: Plasma anticoagulant mechanism of heparin, heparan sulfate and dermatan sulfate. Ann NY Acad Sci 556:123- 131, 1989.
6. Abbadini M, Jin Zhu G, Maggi A, et al: Dermatan sulfate induces plasminogen activator release in the perfused rat hindquarters. Blood 70:1858-1860, 1987.
7. Hoppensteadt D, Walenga JM, Farced J: Comparative antithrombotic and haemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 60:191-200, 1990.
8. Desnoyers P, Bara L, Samama M: Dermatan sulphate et prevention des trombes veineuses experimentales. Path Biol 37:759-767, 1989.
9. Van Ryn J, Mckenna J, Gray E, et al: Effects of sulphated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 61:7-9, 1989.
10. Maggi A, Abbadini A, Pagella PG, et al: Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemostasis 17:329-335, 1987.
11. Mascellani G, Bianchini P: European Patent 1990, No. 0221977. USA Patent 1990, No. 4973580.
12. Barbanti M, Calanni F, Babbini M, et al: Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Thromb Res 71:417-422, 1993.
13. Barbanti M, Calanni F, Milani MR, et al: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis - evidence for an anticoagulant-independent mechanism. Thromb Haemost 69:147-151, 1993.
14. Bergonzini GL, Bianchini P, Hoppensteadt D, et al: Pharmacokinetics of native and low molecular weight dermatan: Preliminary results in rats and primates. Semin Thromb Haemost 17 (suppl 2): 235-239, 1991.
15. Legnani C, Palareti G, Biagi R, et al: Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (Desmin 370) in healthy subjects. Eur J Clin Pharmacol 47:247- 252, 1994.
16. Dettori AG, Galli G, Manotti C, et al: Pharmacological activity of a low molecular weight dermatan sulphate (Desmin) in healthy volunteers. Semin Thromb Hemost 20:259-265, 1994.
17. Tamagnone G. Barbanti M: Desmin-370 Drugs Fut. 19:638-640, 1994.
18. Barbanti M, Calanni F, Marchi E, et al: Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in experimental venous thrombosis in rat: Comparison with t-PA and u-PA. Thromb Haemost 69:860, 1993 (abstract).
19. Barbanti M, Calanni F, Marchi E, et al: Desmin 370, a low molecular weight dermatan sulphate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrood. Thromb Haemost 73:287- 290, 1995.
20. Harenberg J, Jeschek M, Acker M, et al: Pharmacodynamic effect of low molecular weight dermatan sulphate. Thromb Haemost 69:674, 1993 (abstract).
21. Dol F, Houin G, Rostin M, et al: Pharmacodynamics and pharmacokinetics of dermatan sulfate in hu- mans. Blood 74:1577-1582, 1989.
22. Cucinotta D, Manopulo R, Galati M, et al: Pharmacodynamics of a new low-molecular weight dermatan sulphate after a single subcutaneous injection in elderly patients with chronic venous disorders: A phase 1 trial. Curr Ther Res 55:1492- 1500, 1994.
23. Traini AM, Cervi V, Melandri G, et al: Pharmacodynamic characteristic of low-molecular weight dermatan sulphate after a single subcutaneous administration in acute myocardial infarction. J Int Med Res 22:323-331, 1994.